This site is intended for healthcare professionals only
LoginRegister

USFDA completes inspection at Dr Reddy's Labs Bachupally RnD centre

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli   |  
USFDA inspection
  • whatsapp
  • Telegram

Hyderabad: In a recent BSE filing, Dr Reddy's Labs has informed that the United States Food & Drug Administration (USFDA) has completed a routine Good Manufacturing Practice (GMP) inspection at the Company's R&D centre (Integrated Product Development Organisation or IPDO) in Bachupally, Hyderabad with zero observations.

The inspection was conducted from 16th September to 20th September, 2024.

Read also: Dr Sridevi Khambhampaty appointed as CEO of Shilpa Biologicals

Medical Dialogues team had earlier reported that Dr Reddy's Labs had received the Establishment Inspection Report (EIR) from the USFDA for the formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad.

Read also: Dr Reddy's Labs gets USFDA EIR for Bachupally facility

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe


dr reddys labsdr reddys labs newsUSFDAUSFDA inspection
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    X